Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02559505 · ClinicalTrials.gov registry record · NA

Influenza Immunity in Children

A NA study, sponsored by University of Rochester.

Completed
Registry status
NA
Development phase
134
Enrollment target

NCT02559505 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 134 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02559505, a NA study, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
NA
Development phase
134 participants
Enrollment target

Study Summary

This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.

Interventions

  • BIOLOGICAL Seasonal IIV 0.25 mL dose
  • OTHER Natural influenza infection
  • BIOLOGICAL Seasonal IIV 0.5 mL dose

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2015-10
Est. Completion 2020-07-03
Phase NA

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT02559505

The ClinicalTrials.gov registry entry for NCT02559505 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Seasonal IIV 0.25 mL dose is the first listed.

NCT02559505 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02559505 about?

NCT02559505 is a clinical study titled "Influenza Immunity in Children". This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.

What is the current status of trial NCT02559505?

This trial is currently completed. It is a NA study. The enrollment target is 134 participants. The study started on 2015-10. Estimated completion is 2020-07-03.

What interventions are being tested in trial NCT02559505?

The interventions under investigation include: Seasonal IIV 0.25 mL dose (BIOLOGICAL), Natural influenza infection (OTHER), Seasonal IIV 0.5 mL dose (BIOLOGICAL).

Who is sponsoring clinical trial NCT02559505?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.